Neoadjuvant Immune Checkpoint Inhibitor Therapy in TMB-High Rectal Adenocarcinoma

Default Digital Object Group 2026 Dataset

View at publisher
DOI: 10.1200/adn.26.300320
Cited by: 0

Abstract

Patients with rectal adenocarcinomas that are tumor mutational burden–high and DNA mismatch repair–deficient/microsatellite unstable or that harbor pathologic mutations in POLE/POLD1 should be considered for neoadjuvant immune checkpoint inhibitor therapy.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Colorectal Cancer Surgical Treatments Genetic factors in colorectal cancer

Publication details

Journal / source
Default Digital Object Group
Publication date
28 January 2026
Document type
Dataset